Eli Lilly says retatrutide combo regimen drives record weight loss in mid-stage trial

Eli Lilly says its closely watched combination obesity regimen, including GLP-1 drug retatrutide, produced record weight loss in a mid-stage trial; in patients with Type 2 diabetes, retatrutide helped participants lose up to 60 pounds, about 23% of body weight, according to the new trial results.

Detected & updated continuously · Source: Nebula